Organization
Willamette Valley Cancer Institute and Research Center, US Oncology Research
2 abstracts
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,